Artiva Biotherapeutics (NASDAQ:ARTV) Receives New Coverage from Analysts at Cantor Fitzgerald

Analysts at Cantor Fitzgerald started coverage on shares of Artiva Biotherapeutics (NASDAQ:ARTV) in a note issued to investors on Tuesday, Marketbeat Ratings reports. The brokerage set an “overweight” rating and a $23.00 price target on the stock. Cantor Fitzgerald’s target price suggests a potential upside of 101.22% from the company’s current price.

ARTV has been the topic of several other research reports. Wedbush initiated coverage on shares of Artiva Biotherapeutics in a research report on Tuesday. They issued an “outperform” rating and a $18.00 target price on the stock. Needham & Company LLC started coverage on shares of Artiva Biotherapeutics in a research note on Tuesday. They set a “buy” rating and a $23.00 target price on the stock. Finally, TD Cowen started coverage on shares of Artiva Biotherapeutics in a research note on Tuesday. They issued a “buy” rating on the stock. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $21.25.

Artiva Biotherapeutics Trading Up 2.1 %

Shares of Artiva Biotherapeutics stock opened at $11.43 on Tuesday. Artiva Biotherapeutics has a 1 year low of $10.50 and a 1 year high of $16.00.

Insider Activity at Artiva Biotherapeutics

In other news, Director Yong-Jun Huh acquired 2,083,332 shares of the business’s stock in a transaction on Monday, July 22nd. The stock was bought at an average price of $12.00 per share, for a total transaction of $24,999,984.00. Following the transaction, the director now owns 3,306,900 shares in the company, valued at $39,682,800. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Artiva Biotherapeutics news, Director Yong-Jun Huh acquired 2,083,332 shares of the stock in a transaction that occurred on Monday, July 22nd. The shares were purchased at an average cost of $12.00 per share, with a total value of $24,999,984.00. Following the purchase, the director now owns 3,306,900 shares in the company, valued at $39,682,800. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Global Strategic Fund I. Venbio acquired 416,666 shares of the business’s stock in a transaction dated Monday, July 22nd. The shares were bought at an average price of $12.00 per share, for a total transaction of $4,999,992.00. Following the completion of the acquisition, the insider now owns 1,936,637 shares in the company, valued at $23,239,644. The disclosure for this purchase can be found here.

About Artiva Biotherapeutics

Artiva Biotherapeutics Inc is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. The company’s lead program includes AlloNK(R). Artiva Biotherapeutics Inc is based in SAN DIEGO.